Terms: = Uterine cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Clinical Outcome
81 results:
1. Genomic profile analysis of leiomyomas with bizarre nuclei and fumarate hydratase deficient leiomyomas: Strengths, weaknesses, and limitations of array-CGH interpretation.
Fontanges Q; Dubos P; Lesluyes T; Laizet Y; Velasco V; Meléndez B; D'Haene N; Oliva E; Young RH; Mayeur L; Rebier F; Alamé M; Larmonier C; Devouassoux-Shisheboran M; Arnould L; Soubeyran I; Chakiba C; Floquet A; Babin G; Guyon F; Mery E; Le Guellec S; Noël JC; Croce S; Chibon F
Genes Chromosomes Cancer; 2024 Mar; 63(3):e23229. PubMed ID: 38481055
[TBL] [Abstract] [Full Text] [Related]
2. Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies.
Recio F; Scalise CB; Loar P; Lumish M; Berman T; Peddada A; Kalashnikova E; Rivero-Hinojosa S; Beisch T; Nicosia B; Farmer T; Dutta P; Malhotra M; ElNaggar AC; Liu MC; Vaccarello L; Holloway RW
Gynecol Oncol; 2024 Mar; 182():63-69. PubMed ID: 38262240
[TBL] [Abstract] [Full Text] [Related]
3. Evaluation of somatic mutations in cervicovaginal samples as a non-invasive method for the detection and molecular classification of endometrial cancer.
Pelegrina B; Paytubi S; Marin F; Martínez JM; Carmona Á; Frias-Gomez J; Peremiquel-Trillas P; Dorca E; Zanca A; López-Querol M; Onieva I; Benavente Y; Barahona M; Fernandez-Gonzalez S; De Francisco J; Caño V; Vidal A; Pijuan L; Canet-Hermida J; Dueñas N; Brunet J; Pineda M; Matias-Guiu X; Ponce J; Bosch FX; De Sanjosé S; Alemany L; Costas L
EBioMedicine; 2023 Aug; 94():104716. PubMed ID: 37480623
[TBL] [Abstract] [Full Text] [Related]
4. Pure and mixed clear cell carcinoma of the endometrium: A molecular and immunohistochemical analysis study.
Reijnen C; Vrede SW; Eijkelenboom A; Draak R; Sweegers S; Snijders MPLM; van Gestel P; Pijnenborg JMA; Bulten J; Küsters-Vandevelde HVN
Cancer Med; 2023 Jun; 12(11):12365-12376. PubMed ID: 37081760
[TBL] [Abstract] [Full Text] [Related]
5. clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.
Madariaga A; Garg S; Tchrakian N; Dhani NC; Jimenez W; Welch S; MacKay H; Ethier JL; Gilbert L; Li X; Rodriguez A; Chan L; Bowering V; Clarke B; Zhang T; King I; Downs G; Stockley T; Wang L; Udagani S; Oza AM; Lheureux S
Nat Commun; 2023 Mar; 14(1):1452. PubMed ID: 36922497
[TBL] [Abstract] [Full Text] [Related]
6. It is more than uterine fibroids: Incidental discovery of adenoma malignum of the cervix.
Abada E
Malays J Pathol; 2022 Dec; 44(3):533-538. PubMed ID: 36591722
[TBL] [Abstract] [Full Text] [Related]
7. Lymph-vascular Space Involvement and/or p53 Overexpression Correlated With the clinical outcome of Early-stage Endometrial cancer Patients Treated With Adjuvant Vaginal Brachytherapy.
Laliscia C; Gadducci A; Coccia N; Mattioni R; Fuentes T; Caretto M; Pistolesi S; Puccini P; Perrone F; Morganti R; Paiar F
Anticancer Res; 2023 Jan; 43(1):149-156. PubMed ID: 36585177
[TBL] [Abstract] [Full Text] [Related]
8. Prohibitin 1 interacts with p53 in the regulation of mitochondrial dynamics and chemoresistance in gynecologic cancers.
Kong B; Han CY; Kim SI; Patten DA; Han Y; Carmona E; Shieh DB; Cheung AC; Mes-Masson AM; Harper ME; Song YS; Tsang BK
J Ovarian Res; 2022 Jun; 15(1):70. PubMed ID: 35668443
[TBL] [Abstract] [Full Text] [Related]
9. clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma.
Kobayashi Kato M; Asami Y; Takayanagi D; Matsuda M; Shimada Y; Hiranuma K; Kuno I; Komatsu M; Hamamoto R; Matsumoto K; Ishikawa M; Kohno T; Kato T; Shiraishi K; Yoshida H
Cancer Sci; 2022 May; 113(5):1712-1721. PubMed ID: 35278272
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
Leon-Castillo A; Horeweg N; Peters EEM; Rutten T; Ter Haar N; Smit VTHBM; Kroon CD; Boennelycke M; Hogdall E; Hogdall C; Nout RRA; Creutzberg CL; Ortoft G; Bosse T
Gynecol Oncol; 2022 Mar; 164(3):577-586. PubMed ID: 35078648
[TBL] [Abstract] [Full Text] [Related]
11. A retrospective study on incidence, diagnosis, and clinical outcome of gastric-type endocervical adenocarcinoma in a single institution.
Radomska A; Lee D; Neufeld H; Korte N; Torlakovic E; Agrawal A; Chibbar R
Diagn Pathol; 2021 Jul; 16(1):68. PubMed ID: 34332600
[TBL] [Abstract] [Full Text] [Related]
12. HPV transcript expression affects cervical cancer response to chemoradiation.
Ruiz FJ; Inkman M; Rashmi R; Muhammad N; Gabriel N; Miller CA; McLellan MD; Goldstein M; Markovina S; Grigsby PW; Zhang J; Schwarz JK
JCI Insight; 2021 Aug; 6(16):. PubMed ID: 34255749
[TBL] [Abstract] [Full Text] [Related]
13. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome.
Hollis RL; Thomson JP; Stanley B; Churchman M; Meynert AM; Rye T; Bartos C; Iida Y; Croy I; Mackean M; Nussey F; Okamoto A; Semple CA; Gourley C; Herrington CS
Nat Commun; 2020 Oct; 11(1):4995. PubMed ID: 33020491
[TBL] [Abstract] [Full Text] [Related]
14. Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy.
Yoshimoto Y; Sasaki Y; Murata K; Noda SE; Miyasaka Y; Hamamoto J; Furuya M; Hirato J; Suzuki Y; Ohno T; Tokino T; Oike T; Nakano T
Gynecol Oncol; 2020 Nov; 159(2):546-553. PubMed ID: 32951893
[TBL] [Abstract] [Full Text] [Related]
15. Corded and Hyalinized Endometrioid Adenocarcinoma (CHEC) of the uterine Corpus are Characterized by CTNNB1 Mutations and Can Show Adverse clinical outcomes.
Ladwig NR; Umetsu SE; Zaloudek C; Rabban J; Garg K
Int J Gynecol Pathol; 2021 Mar; 40(2):103-115. PubMed ID: 32909971
[TBL] [Abstract] [Full Text] [Related]
16. Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.
Reijnen C; Küsters-Vandevelde HVN; Ligtenberg MJL; Bulten J; Oosterwegel M; Snijders MPLM; Sweegers S; de Hullu JA; Vos MC; van der Wurff AAM; van Altena AM; Eijkelenboom A; Pijnenborg JMA
Int J Cancer; 2020 Jul; 147(2):478-489. PubMed ID: 32022266
[TBL] [Abstract] [Full Text] [Related]
17. Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.
León-Castillo A; Gilvazquez E; Nout R; Smit VT; McAlpine JN; McConechy M; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Soslow RA; Ganesan R; Matias-Guiu X; Oliva E; Harrison BT; Church DN; Gilks CB; Bosse T
J Pathol; 2020 Mar; 250(3):312-322. PubMed ID: 31829447
[TBL] [Abstract] [Full Text] [Related]
18. Germline
de Jonge MM; Ritterhouse LL; de Kroon CD; Vreeswijk MPG; Segal JP; Puranik R; Hollema H; Rookus MA; van Asperen CJ; van Leeuwen FE; Smit VTHBM; Howitt BE; Bosse T;
Clin Cancer Res; 2019 Dec; 25(24):7517-7526. PubMed ID: 31492746
[TBL] [Abstract] [Full Text] [Related]
19. Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables.
Gadducci A; Guerrieri ME; Cosio S
Crit Rev Oncol Hematol; 2019 Mar; 135():103-114. PubMed ID: 30819439
[TBL] [Abstract] [Full Text] [Related]
20. Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer.
Polychronidou G; Kotoula V; Manousou K; Kostopoulos I; Karayannopoulou G; Vrettou E; Bobos M; Raptou G; Efstratiou I; Dionysopoulos D; Chatzopoulos K; Lakis S; Chrisafi S; Tsolakidis D; Papanikolaou A; Dombros N; Fountzilas G
PLoS One; 2018; 13(12):e0208221. PubMed ID: 30521558
[TBL] [Abstract] [Full Text] [Related]
[Next]
